The S-4/A confirms the near-complete transfer of control to Slate. The key binary event is the Fulcrum stockholder vote — if approved, FULC shares will trade post-merger as SLTE with minimal legacy Fulcrum ownership. The ~$270M special dividend provides a floor for FULC's current valuation, but the stock will likely trade near the dividend-adjusted net cash value until the vote. Monitor the special meeting date and any potential competing proposals.
Price Chart
Executive Summary
Fulcrum Therapeutics (FULC) filed Amendment No. 2 to its S-4 registration statement, detailing the proposed reverse merger with privately held Slate Medicines. The transaction, structured as a reverse recapitalization, will result in pre-Merger Slate stockholders (excluding concurrent investors) owning ~55.9%, new investors ~39.1%, and pre-Merger Fulcrum stockholders only ~5.0% of the combined company on a fully diluted basis. Fulcrum stockholders will receive a special pre-closing cash dividend of approximately $270 million, but the deal represents a near-total loss of equity ownership for current FULC holders.
Key Facts
- Pre-Merger Fulcrum stockholders expected to own only ~5.0% of the combined company on a fully diluted basis.
- Pre-Merger Slate stockholders (excluding investors) expected to own ~55.9%, and new investors ~39.1%.
- Fulcrum stockholders to receive a special pre-closing cash dividend of approximately $270 million.
- Fulcrum valued at $31.3 million for the exchange ratio calculation, subject to downward adjustment if net cash at closing is below $20.3 million.
- Slate valued at $350.0 million, exclusive of concurrent investment proceeds.
- Slate Concurrent Investment of ~$245 million from existing and new investors, including Frazier Life Sciences.
- Combined company will be named Slate Medicines, Inc. and trade under ticker SLTE.
- Slate's lead candidate is SLTE-1009, a Phase 1 monoclonal antibody targeting PACAP/VIP for migraine prevention.
- Fulcrum discontinued its only clinical program (pociredir) in June 2026 and reduced workforce by ~85%.
- Fulcrum's board recommends voting FOR all proposals; ~1% of Fulcrum stockholders have signed support agreements.
- Fulcrum CEO Alex Sapir and all current Fulcrum directors will resign; Slate management will take over.
- Transaction expected to close in Q4 2026.
- Fulcrum's net loss was $74.9M for FY2025 and $45.1M for H1 2026; accumulated deficit of $639.3M as of June 30, 2026.
- Slate's net loss was $4.5M for Q2 2026 and $1.3M for FY2025; accumulated deficit of $17.1M as of June 30, 2026.
Financial Impact
Pre-Merger Fulcrum stockholders face ~95% dilution of their equity stake in the combined company, offset by a ~$270M special cash dividend (~$5.40 per share based on ~50M shares outstanding). Fulcrum's enterprise value is effectively $31.3M vs. Slate's $350M.
Risk Factors
- Fulcrum stockholders may vote down the deal, leaving Fulcrum with no pipeline and a cash burn.
- Nasdaq listing for combined company may not be approved, creating liquidity risk.
- Slate's lead candidate SLTE-1009 is in Phase 1 with no human data yet — high clinical risk.
- The exchange ratio is fixed based on net cash, not market price, creating valuation mismatch risk.
- Litigation risk from stockholder lawsuits challenging the merger terms.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-426840 |
| Document: d127837dex109.htm | 0001193125-26-426840 |
| Document: d127837dex1010.htm | 0001193125-26-426840 |
| Document: d127837dex1011.htm | 0001193125-26-426840 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | S-4/A | $3.70 $3.68 | ▲ +0.54% | ▼ −0.64% | $3.72 (−0.68%) |
Oct 8, 2026 18d ago | S-4/A | $3.77 $3.75 | ▼ −0.53% | ▼ −0.47% | $3.72 (−1.19%) |
Sep 1, 2026 7w ago | S-4 | $3.85 $3.84 | ▲ +0.26% | ▲ +1.31% | $3.72 (+3.25%) |
Aug 17, 2026 10w ago | 425 | $3.84 $3.87 | ▼ −0.78% | ▼ −1.46% | $3.72 (+2.99%) |
Aug 17, 2026 10w ago | 425 | $3.84 $3.87 | ▲ +0.78% | ▲ +1.46% | $3.72 (−2.99%) |
Aug 17, 2026 10w ago | 8-K | $3.84 $3.87 | ▲ +0.78% | ▲ +1.46% | $3.72 (−2.99%) |
Aug 17, 2026 10w ago | Press Release | $3.84 $3.87 | ▲ +0.78% | ▲ +1.46% | $3.72 (−2.99%) |
Aug 10, 2026 11w ago | 8-K | $3.75 $3.69 | ▼ −1.60% | ▼ −1.28% | $3.72 (−0.67%) |
Jul 15, 2026 14w ago | 3 | $3.50 $3.65 | ▲ +4.29% | ▲ +5.28% | $3.72 (+6.43%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.55 $3.45 | ▼ −2.82% | ▼ −3.36% | $3.72 (+4.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers